University of Washington trial of Rylaze in adult ALL remains suspended for safety review
The phase II study combining DA-EPOCH chemotherapy with Jazz Pharmaceuticals' recombinant Erwinia asparaginase in newly diagnosed adult leukemia patients stays halted, per a registry update posted September 29, 2026.
A phase II trial testing dose-adjusted DA-EPOCH chemotherapy, with or without rituximab, plus recombinant Erwinia asparaginase (JZP458, marketed as Rylaze) remains suspended. The ClinicalTrials.gov record lists the overall status as suspended, with the reason given as Safety Review, and shows a last update posted date of September 29, 2026.1
The study, registered as NCT06738368, is sponsored by the University of Washington with Jazz Pharmaceuticals listed as a collaborator1. Its start date is listed as May 8, 2026 (actual), with first posting on December 17, 2024, an estimated primary completion date of January 31, 2028, and an estimated study completion date of July 30, 2028.1
The trial targets newly-diagnosed adults with Philadelphia chromosome-negative B-acute lymphoblastic leukemia or T-acute lymphoblastic leukemia1. Under the protocol, patients receive etoposide, doxorubicin and vincristine intravenously over 96 hours on days 1-4, cyclophosphamide over 1 hour on day 5, oral prednisone twice daily on days 1-5, and JZP458 intramuscularly once every 2-3 days on days 7-21 for up to 7 doses, with cycles repeating every 21 days for up to 8 cycles absent disease progression or unacceptable toxicity.1 CD20-positive patients also receive rituximab intravenously on day 1 or 5 of each cycle.1
The trial's primary outcome is measurable residual disease negativity after 4 cycles of treatment, measured by multi-parameter flow cytometry and assessed according to National Comprehensive Cancer Network response criteria.1 Enrollment is estimated at 30 participants1 at a single U.S. site, the Fred Hutch/University of Washington Cancer Consortium in Seattle, Washington.1 The record provides no further detail on the nature of the safety concern prompting the suspension.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.